Stem cells with a view: a look inside a retinal ciliopathy
Editorial

Stem cells with a view: a look inside a retinal ciliopathy

Linjing Li, Hemant Khanna

Department of Ophthalmology, UMASS Medical School, Worcester, MA 01605, USA

Correspondence to: Hemant Khanna, PhD. Department of Ophthalmology, UMASS Medical School, AS6-2043, Albert Sherman Center, 368 Plantation St., Worcester, MA 01605, USA. Email: hemant.khanna@umassmed.edu.

Received: 14 September 2016; Accepted: 23 September 2016; Published: 21 October 2016.

doi: 10.21037/sci.2016.09.19


Ciliopathies are a group of severe developmental disorders that are clinically and genetically heterogeneous. They occur due to the dysfunction of cilia, which are microtubule-based extensions of the plasma membrane. The ciliary membrane acts as a hub for transmembrane receptors and specific lipids and proteins that assist in the detection and downstream signaling of extrinsic cues. They carry out diverse signaling cascades, such as sonic hedgehog signaling and sensory perceptions, including olfaction, chemosensation and photoreception (1,2). Not surprisingly, ciliary dysfunction results in severe developmental and systemic disorders, including Meckel-Gruber Syndrome, Joubert Syndrome, Bardet-Biedl Syndrome, and Senior-Loken Syndrome (1).

Retinal degeneration due to ciliary dysfunction is commonly observed in ciliopathies (3). It is predominantly caused due to the dysfunction and degeneration of the ciliary outer segment of the photoreceptors, the light-sensing neurons in the retina. Surprisingly however, photoreceptor degeneration due to ciliary dysfunction can also manifest as an isolated case with no systemic manifestations. An example of such an observation is mutations in the ciliary protein-encoding gene CEP290. In 2006, the CEP290 gene was cloned as a causative gene for Joubert Syndrome (4,5). Subsequently, CEP290 mutations were identified in a wide range of ciliopathies and were associated with a spectrum of systemic manifestations, including mental retardation, polydactyly, renal failure and retinal dystrophies (6-10). Simultaneous studies also identified a spontaneously occurring mouse mutant of Cep290, Cep290rd16 (retinal degeneration 16) (11). The Cep290rd16 mouse carries an in-frame deletion of exons 16–19 and interestingly, predominantly exhibits early onset severe retinal degeneration. No other systemic manifestations were observed. Such a retina-restricted phenotype was attributed to the expression of a partially functional deleted variant of CEP290, in the Cep290rd16 mouse, which might spare other cell types but was detrimental to photoreceptors.

Building upon these observations, CEP290 mutations, particularly a deep intronic homozygous CEP290 mutation, c.2991 + 1665A>G, were reported in isolated cases of childhood blindness disorder, Leber congenital amaurosis (LCA) (12). This mutation creates a cryptic exon between exons 26 and 27 with a premature stop codon in the CEP290 gene. Curiously, patient lymphocytes carrying this intronic mutation express, albeit at lower level the wild type CEP290 transcript as well (12). Thus, it was hypothesized that non-retinal cell types may escape the splice defect more efficiently and result in the production of near-normal normal levels of the full-length CEP290 transcript; however, such a mechanism might not be functional in the photoreceptors. Investigating such mechanisms is key to our understanding of the molecular underpinnings of the manifestation of retina-specific disease due to CEP290 mutations.

In a recent study, Parfitt et al. (13) took on this challenging question. They resorted to induced pluripotent stem cells (iPSCs) to not only investigate the disease mechanisms but also to develop rational therapeutic modalities. They generated iPSCs from fibroblasts (14,15) of control subjects or from CEP290-LCA patients carrying the deep intronic mutation c.2991 + 1665A>G. Using previously published procedures they differentiated the iPSCs into optic cups and the RPE (16). The authors then compared the effect of the mutation on the splicing of the CEP290 gene in the iPSCs as well as in the differentiated 3-dimensional (3D) optic cups (to induce retina and photoreceptor formation) and the RPE. The authors first found that the three cell types derived from control fibroblasts exhibited differential regulation of the CEP290 transcription levels. This observation led them to hypothesize that differential expression of the CEP290 gene may underlie a tissue-specific effect of some CEP290 mutations. Commensurately, they found that such regulation is altered due to the deep intronic mutation. It resulted in aberrant splicing of the CEP290 gene and concomitantly reduced CEP290 protein levels in the mutant iPSCs as compared to controls. The mutant iPSCs derived retinas and photoreceptors exhibited relatively severe deregulation of CEP290 expression; they exhibited fewer cilia predominantly in the photoreceptors and defective cilia formation and localization of retinitis pigmentosa GTPase regulator (RPGR), a CEP290-interacting retinal ciliopathy protein (17,18) and small GTPase RAB8A.

Antisense oligonucleotide (AON)-mediated splice modulation is a powerful tool to correct splice site defects in disease genes. In fact, AON-mediated correction of the c.2991 + 1665A > G CEP290 mutation in patient-derived fibroblasts was demonstrated in two independent studies (19,20). The corrected gene exhibited improved transcription of the wild type transcript and restoration of cilia formation in the patient fibroblasts. Building upon the success of these studies, Parfitt et al., designed a 25-bp antisense morpholino (MO) against the c.2991 + 1665A>G CEP290 mutation and tested its efficacy. They found that the CEP290-MO reduced the levels of the cryptic exon inclusion and resulted in a concomitant increase in the normal transcript levels in LCA fibroblasts. The CEP290-MO treatment also restored ciliation defects and ciliary protein trafficking of RPGR, and of opsins in the 3D-optic cup derived photoreceptors (13).

The differentiated retinal tissue has provided an excellent platform to also assess the efficacy of other gene correction strategies, such as genome editing. However, such approaches will have to be continuously designed and modified to fit the patient mutation. Future studies should also focus on utilizing the differentiated tissues from patients to explore the efficacy of mutation-independent approaches. Previous studies using the Cep290rd16 mouse and the zebrafish have identified potential pathway intermediates that can be exploited to mitigate or delay photoreceptor degeneration due to the loss of CEP290 (21,22). Such approaches can also be readily tested in the differentiated optic cups. Taken together, the results of Parfitt et al. provide a valuable clue to our understanding of the tissue-enriched or tissue-specific disease manifestations in several clinically heterogeneous ciliopathies. In addition, this study has opened new and exciting avenues to design and test novel therapeutic modalities for several blinding diseases.


Acknowledgements

Funding: The work in the laboratory of HK is supported by grants from the National Eye Institute (EY022372), Foundation Fighting Blindness, and University of Massachusetts Center for Clinical and Translational Sciences.


Footnote

Provenance: This is a Guest Editorial commissioned by Editor-in-Chief Zhizhuang Joe Zhao (Pathology Graduate Program, University of Oklahoma Health Sciences Center, Oklahoma City, USA).

Conflicts of Interest: The authors have no conflicts of interest to declare.

Comment on: Parfitt DA, Lane A, Ramsden CM, et al. Identification and Correction of Mechanisms Underlying Inherited Blindness in Human iPSC-Derived Optic Cups. Cell Stem Cell 2016;18:769-81.


References

  1. Badano JL, Mitsuma N, Beales PL, et al. The ciliopathies: an emerging class of human genetic disorders. Annu Rev Genomics Hum Genet 2006;7:125-48. [Crossref] [PubMed]
  2. Singla V, Reiter JF. The primary cilium as the cell's antenna: signaling at a sensory organelle. Science 2006;313:629-33. [Crossref] [PubMed]
  3. Khanna H, Baehr W. Retina ciliopathies: from genes to mechanisms and treatment. Vision Res 2012;75:1. [Crossref] [PubMed]
  4. Sayer JA, Otto EA, O'Toole JF, et al. The centrosomal protein nephrocystin-6 is mutated in Joubert syndrome and activates transcription factor ATF4. Nat Genet 2006;38:674-81. [Crossref] [PubMed]
  5. Valente EM, Silhavy JL, Brancati F, et al. Mutations in CEP290, which encodes a centrosomal protein, cause pleiotropic forms of Joubert syndrome. Nat Genet 2006;38:623-5. [Crossref] [PubMed]
  6. Baala L, Audollent S, Martinovic J, et al. Pleiotropic effects of CEP290 (NPHP6) mutations extend to Meckel syndrome. Am J Hum Genet 2007;81:170-9. [Crossref] [PubMed]
  7. Helou J, Otto EA, Attanasio M, et al. Mutation analysis of NPHP6/CEP290 in patients with Joubert syndrome and Senior-Løken syndrome. J Med Genet 2007;44:657-63. [Crossref] [PubMed]
  8. Perrault I, Delphin N, Hanein S, et al. Spectrum of NPHP6/CEP290 mutations in Leber congenital amaurosis and delineation of the associated phenotype. Hum Mutat 2007;28:416. [Crossref] [PubMed]
  9. Rachel RA, May-Simera HL, Veleri S, et al. Combining Cep290 and Mkks ciliopathy alleles in mice rescues sensory defects and restores ciliogenesis. J Clin Invest 2012;122:1233-45. [Crossref] [PubMed]
  10. Coppieters F, Lefever S, Leroy BP, et al. CEP290, a gene with many faces: mutation overview and presentation of CEP290base. Hum Mutat 2010;31:1097-108. [Crossref] [PubMed]
  11. Chang B, Khanna H, Hawes N, et al. In-frame deletion in a novel centrosomal/ciliary protein CEP290/NPHP6 perturbs its interaction with RPGR and results in early-onset retinal degeneration in the rd16 mouse. Hum Mol Genet 2006;15:1847-57. [Crossref] [PubMed]
  12. den Hollander AI, Koenekoop RK, Yzer S, et al. Mutations in the CEP290 (NPHP6) gene are a frequent cause of Leber congenital amaurosis. Am J Hum Genet 2006;79:556-61. [Crossref] [PubMed]
  13. Parfitt DA, Lane A, Ramsden CM, et al. Identification and Correction of Mechanisms Underlying Inherited Blindness in Human iPSC-Derived Optic Cups. Cell Stem Cell 2016;18:769-81. [Crossref] [PubMed]
  14. Nakano T, Ando S, Takata N, et al. Self-formation of optic cups and storable stratified neural retina from human ESCs. Cell Stem Cell 2012;10:771-85. [Crossref] [PubMed]
  15. Okita K, Matsumura Y, Sato Y, et al. A more efficient method to generate integration-free human iPS cells. Nat Methods 2011;8:409-12. [Crossref] [PubMed]
  16. Zhong X, Gutierrez C, Xue T, et al. Generation of three-dimensional retinal tissue with functional photoreceptors from human iPSCs. Nat Commun 2014;5:4047. [Crossref] [PubMed]
  17. Rao KN, Zhang W, Li L, et al. Ciliopathy-associated protein CEP290 modifies the severity of retinal degeneration due to loss of RPGR. Hum Mol Genet 2016;25:2005-12. [Crossref] [PubMed]
  18. Anand M, Khanna H. Ciliary transition zone (TZ) proteins RPGR and CEP290: role in photoreceptor cilia and degenerative diseases. Expert Opin Ther Targets 2012;16:541-51. [Crossref] [PubMed]
  19. Collin RW, den Hollander AI, van der Velde-Visser SD, et al. Antisense Oligonucleotide (AON)-based Therapy for Leber Congenital Amaurosis Caused by a Frequent Mutation in CEP290. Mol Ther Nucleic Acids 2012;1:e14. [Crossref] [PubMed]
  20. Gerard X, Perrault I, Hanein S, et al. AON-mediated Exon Skipping Restores Ciliation in Fibroblasts Harboring the Common Leber Congenital Amaurosis CEP290 Mutation. Mol Ther Nucleic Acids 2012;1:e29. [Crossref] [PubMed]
  21. Murga-Zamalloa CA, Ghosh AK, Patil SB, et al. Accumulation of the Raf-1 kinase inhibitory protein (Rkip) is associated with Cep290-mediated photoreceptor degeneration in ciliopathies. J Biol Chem 2011;286:28276-86. [Crossref] [PubMed]
  22. Subramanian B, Anand M, Khan NW, et al. Loss of Raf-1 kinase inhibitory protein delays early-onset severe retinal ciliopathy in Cep290rd16 mouse. Invest Ophthalmol Vis Sci 2014;55:5788-94. [Crossref] [PubMed]
doi: 10.21037/sci.2016.09.19
Cite this article as: Li L, Khanna H. Stem cells with a view: a look inside a retinal ciliopathy. Stem Cell Investig 2016;3:62.

Refbacks

  • There are currently no refbacks.